Page 189 - COMMUNITY PHARMACY PRACTICE
P. 189
02/04/2024
382
IMPORTANT
• The FDA is now requiring a boxed warning for
montelukast (Singulair) to strengthen the existing warning
about the risk of neuropsychiatric events. (agitation,
depression, sleeping problems, and suicidal thoughts and
actions)
• Montelukast is approved to prevent asthma attacks and
for long-term treatment of asthma in adults and children
aged 1 year or older. It is also approved to prevent
exercise-induced asthma in patients aged 6 years or
older.
382 383
Pharmacist role in Asthma
https://www.guidelinesinpractice.co.uk/resp
iratory/asthma-the-role-of-the-practice-
pharmacist/454617.article
383
191
